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Context: Apelin and arginine vasopressin are antagonists in the regulation of body fluid and osmotic
homeostasis. There are no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS).
Objective: To investigate plasma apelin levels andplasma apelin to copeptin ratios in patientswith
PPS and healthy volunteers using copeptin as a surrogate marker for arginine vasopressin.
Design, Participants, and Setting: We included 41 patients with PPS in this post hoc analysis of a
prospective studyperformed in tertiary carehospitals in SwitzerlandandGermanyand113healthy
volunteers as a control group.
OutcomeMeasures:Plasmaapelinandcopeptin levelsweremeasured in15patientswith complete
central diabetes insipidus (DI), seven patients with complete nephrogenic DI, 19 patients with
primary polydipsia (PP), and 113 healthy volunteers.
Results: Plasma apelin levels were highest in patients with complete nephrogenic DI (413 pmol/L;
interquartile range, 332–504 pmol/L; P .01) and lower in patients with PP (190 [172–215] pmol/L; P
 .001) or complete central DI (209 [174–241] pmol/L; P .02) as compared to healthy volunteers (254
[225–311] pmol/L). Plasma apelin to copeptin ratio in patients with PP (53 [38–92] pmol/pmol; P .9)
was similar tohealthy volunteers (57 [37–102]pmol/pmol). In contrast, theapelin to copeptin ratiowas
higher inpatientswith complete centralDI (89 [73–135]pmol/pmol;P .02) and lower inpatientswith
complete nephrogenic DI (7 [6–10] pmol/pmol; P .001) compared to healthy volunteers.
Conclusion: In PP, normal plasma apelin to copeptin ratio attests a normal water homeostasis. In
contrast, in patients with central or nephrogenic DI, the increased or decreased apelin to copeptin
ratio, respectively, reflects a disturbed osmotic and body fluid homeostasis. (J Clin Endocrinol
Metab 101: 1917–1923, 2016)
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Apelin is a neuro-vasoactive peptide (1) derived frompreproapelin, which generates a peptide of 36
amino acids and two shorter active peptides: apelin-17
(K17F) and the pyroglutamyl form of apelin-13 (pE13F)
(1–3). K17F was found to have the highest affinity for the
apelin receptor in humans and rats (4). Apelin and its
receptor have been found in the plasma and in various
tissues including brain and kidney (5–7). Apelin is in-
volved in various processes such as glucose homeostasis,
cell proliferation, angiogenesis, cardiovascular function,
and also in the regulation of body fluid homeostasis (7–9).
In the brain, apelin and its receptor are colocalizedwith
arginine vasopressin (AVP) in magnocellular neurons of
the supraoptic nucleus and the paraventricular hypotha-
lamic nuclei (5, 10). Due to this close colocalization, an
interaction of apelin and AVP has been assumed. In fact,
in lactating rats, central injection of K17F inhibited AVP
neuron activity and led to a decreased release of AVP into
the bloodstreamwith increased aqueous diuresis (5). This
cross-reaction of apelin andAVPhas been shown not only
in rats but also in humans (11). In healthy volunteers, an
increase of plasma osmolality was accompanied by an in-
crease of plasma AVP and a decrease in plasma apelin
levels, whereas a decrease in plasma osmolality upon wa-
ter loading resulted in decreased plasma AVP levels and
increased plasma apelin levels (11). These findings suggest
that apelin is involved in the maintenance of body fluid
homeostasis acting inversely to AVP.
Apelin has also been investigated in pathological states
with high AVP secretion and hyponatremia such as the
syndrome of inappropriate antidiuretic hormone and
heart failure. In these patients, compared to high AVP
levels, inappropriately low apelin levels were found, re-
sulting in an imbalance of AVP and apelin with a distur-
bance in body fluid homeostasis (12).
In addition to the central effect of apelin in the brain,
apelin and its receptor are also expressed in the kidney, re-
sulting in a direct diuretic effect by counteracting the antidi-
ureticeffectofAVPactionontheAVPreceptor type2(V2-R)
inthecollectingducts (6).ThisshowsthatapelinandAVPact
both in the brain and the kidney in an oppositeway tomain-
tain body fluid and osmotic homeostasis.
In patients with polyuria-polydipsia syndrome (PPS),
body fluid and osmoticmaintenance are disturbed.We have
recently shown that copeptin as a surrogate marker of AVP
improves differential diagnosis in patientswith PPS (13, 14).
So far there exist no data about plasma apelin levels and the
plasma apelin to copeptin ratio in patients with PPS.
Subjects and Methods
Setting
This study was a secondary analysis of a prospective multi-
center study (ClinicalTrials.gov no. NCT00757276) (14). A
complete description has been reported previously (14). The pri-
mary endpoint of the original study was to evaluate the diag-
nostic accuracy of copeptin,mirroringAVP secretion, in patients
with different etiologies of PPS. In brief, inclusion criteria were
age 18 years and polyuria of 40 mL/kg/24 h in the presence
of polydipsia. Exclusion criteria were osmotic diuresis due to a
known underlying disorder such as diabetes mellitus, hypercal-
cemia, uncorrected thyroid or adrenal insufficiency, heart fail-
ure, or pregnancy. All patients underwent a standardized com-
bined water deprivation and saline infusion test starting at 8 Am
without prior fluid restriction. Informed consent was obtained
from all patients and healthy volunteers.
Patients
For the purpose of this study, we measured apelin and co-
peptin levels in the remaining blood samples of eight patients
with complete central diabetes insipidus (DI), six patients with
complete nephrogenic DI, and 14 patients with primary poly-
dipsia (PP). In addition, we prospectively enrolled 13 additional
patients with PPS (seven with complete central DI, five with PP,
and one with complete nephrogenic DI). The blood samples to
determine apelin and copeptin levels were drawn at 8 AM before
starting the water deprivation test.
Healthy volunteers
We included data of 113 healthy volunteers from both sexes
as a reference population. A detailed description of the healthy
volunteers has been published previously (12).
Laboratory analysis
Plasmaapelinandcopeptin levelsweredeterminedaspreviously
described (11, 14). In brief, for plasma apelinmeasurements, blood
was sampled into prechilled EDTA-K3 tubes and centrifuged at
1600 g at 4°C for 15minutes. Plasmawas stored at80°C until
batch analysis. For apelin RIA, plasma samples (0.75 mL) were
mixed with 0.05 mL of 1% BSA and 0.25 mL of 3 M HCl and
centrifuged at 1600  g at 4°C for 10 minutes. The supernatants
were collected, and their pHwas adjusted to 6.5 with 12 MNaOH
and 2 M Tris-HCl buffer (pH 7.4). The samples were then mixed
with 1mL of H2O supplemented with 0.1%BSA and loaded onto
a Sep-PakC18 cartridge (Waters Associates), washedwith 2mLof
100% ethanol, and equilibrated with 5 mL of H2O-0.1% BSA.
Apelin peptides were eluted with 1.5 mL of 100% ethanol. The
recovery rate (mean SEM)was 91 3%.The eluateswere dried
and dissolved in 0.32 mL of RIA buffer. Plasma apelin concentra-
tionsweremeasuredbya specificRIA, validated inhumans (11), by
identification of the molecular forms of apelin present in human
plasma in vivo—K17F, pE13F, and to a lesser extent, apelin-36 by
combining HPLC analysis with RIA detection. The detection limit
of the apelin assay was 6 pmol/L, with an intra-assay variability of
3% and an interassay variability of 5%.
Copeptin was assessed in a single blinded batch by a chemi-
luminescence sandwich immunoassay (B_R_A_H_M_S CT-
proAVP LIA; Thermo Scientific Biomarkers) developed byMor-
genthaler et al (15). The detection limit of the copeptin assaywas
0.4 pmol/L, with an intra-assay variability of 3.7–2.5%at 2.14–
514.4 pmol/L and an interassay variability of 22.9–3.6% at
0.58–902.9 pmol/L (14).
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Reference diagnosis
The final diagnosis of PPS was made by two board-certified
endocrinologists in the field, blinded to copeptin and apelin lev-
els, according to three diagnostic components: 1) the results of
the combined water deprivation/saline infusion test; 2) addi-
tional features such as the patient’s history and diagnostic find-
ings (eg, cranial magnetic resonance imaging); and 3) treatment
response. In case of inconclusive test results, the final diagnosis
was based on treatment response (13, 14, 16).
Statistical analyses
Discrete variables are indicated as counts (percentage) and
continuous variables as medians (interquartile ranges) unless
stated otherwise. The apelin to copeptin ratiowas determined by
division.Weused a hierarchical approach and tested first for any
difference between subgroups with the Fisher exact test for cat-
egorical variables and Kruskal-Wallis one-way ANOVA for not
normallydistributedcontinuousvariables; in caseof a significant
result, we used Dunn’s post hoc test for multiple testing to iden-
tify the specific group differences.
Testing was two-tailed, and P  .05 was considered statisti-
cally significant. For statistical analysis, we used GraphPad
Prism version 6.0 for Mac (GraphPad Software) and IBM SPSS
Statistics 22.0.
Results
A total of 113 healthy volunteers and 41 patientswith PPS
were included in this study: 15 patients with complete
central DI, 19 patients with PP, and seven patients with
complete nephrogenic DI.
The median age of all patients was 48 (interquartile
range, 36–56) years, median body mass index (BMI) was
25.6 (22.4–28.9) kg/m2, and 65.9%were female.Median
age (47 [35–61] years) andBMI (24.2 [21.8–26] kg/m2) in
healthy volunteers were similar compared to patients. A
complete description of all baseline characteristics is given
in Table 1. Clinical volume status was euvolemic in 80%
of the patientswith central DI, in 88%of the patientswith
PP, and in 25% of the patients with nephrogenic DI; none
Table 1. Baseline Characteristics
Healthy





n 113 15 19 7
Age, y 47 (35–61) 50 (42–58) 45 (30–50) 61 (55–65) .12
BMI, kg/m2 24 (22–26) 25 (23–29) 26 (20–29) 26 (25–28) .10
Sex, female 58 (51) 9 (60) 13 (68.4) 5 (71.4) .43
Ethnicity, Caucasian n.a. 15 (100) 16 (84.2) 6 (85.7) .27
Current smoker n.a. 7 (46.7) 4 (21.1) 3 (42.9) .23
History of a brain tumor n.a. 6 (40) 1 (5) 0 (0) .02
History of trans-sphenoidal surgery n.a. 7 (46.7) 1 (5) 0 (0) .02
Systolic blood pressure, mm Hg 124 (116–134) 121 (115–137) 124 (110–131) 137 (117–140) .53
Heart rate, bpm 66 (59–74) 70 (67–77) 76 (63–81) 83 (79–85) .0005a
Clinical volume status: hypo-/eu-/
hypervolemic (euvolemic), %
n.a. 3/12/0 (80) 2/14/0 (87.5) 3/1/0 (25) .039
Hemoglobin, g/L n.a. 140 (130–148) 136 (134–143) 128 (115–138) .31
Hematocrit, l/L 0.41 (0.39–0.43) 0.39 (0.38–0.44) 0.40 (0.38–0.43) 0.37 (0.34–0.4) .13
Creatinine, mol/L 76 (65–84) 75 (63–85) 69 (62–74) 146 (125–266) .0001b
Albumin, g/L n.a. 39 (34–40) 37 (36–42) 37 (32–39) .16
Plasma sodium, mmol/L 140 (139–141) 142 (142–144) 141 (140–142) 143 (142–146) .001c
Plasma osmolality, mOsmol/kg H2O 288 (285–291) 297 (292–307) 294 (290–301) 306 (303–312) .001
d
Diuretics 0 (0) 1 (6.7) 0 (0) 0 (0) .54
Lithium 0 (0) 0 (0) 1 (5.3) 5 (71.4) .001
Antiepileptics 0 (0) 1 (6.7) 2 (10.5) 2 (28.6) .29
Corticosteroids 0 (0) 6 (40) 2 (10.5) 0 (0) .06
Narcotics 0 (0) 2 (13.3) 3 (15.8) 4 (57.1) .06
Desmopressin 0 (0) 9 (60) 0 (0) 0 (0) .001
Birth control pill, % of female patients 0 (0) 2 (22) 3 (23) 0 (0) .001
Abbreviation: n.a., not applicable. Data are expressed as number (percentage) or median (interquartile range), unless stated otherwise. P values
were assessed by Fisher’s exact test (categorical variables) and by the Kruskal-Wallis test (continuous variables).
a Patients with nephrogenic DI had significantly higher heart rate values compared to healthy volunteers. P value assessed with Dunn’s multiple
comparison test: P  .004.
b Creatinine levels were significantly higher in patients with nephrogenic DI compared to each other group (central DI, PP, and healthy volunteers).
P  .001 for each comparison assessed with Dunn’s multiple comparison test.
c Sodium values in patients with central DI were significantly higher compared to healthy volunteers. P value assessed with Dunn’s multiple
comparison test: P  .0001.
d Osmolality in healthy volunteers was significantly lower compared to all three patient groups. P values assessed with Dunn’s multiple comparison
test: central DI, P  .0001; PP, P  .0004; nephrogenic DI, P  .004.
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of the patients was hypervolemic. Creatinine levels and
heart rate were higher in patients with nephrogenic DI
compared to all the other groups. Serum sodium levels and
serum osmolality were highest in patients with nephro-
genic DI.
Basal plasmacopeptin andapelin levels aswell as apelin
to copeptin ratio of all four groups (healthy volunteers,
complete centralDI, PP, andcompletenephrogenicDI) are
shown in Table 2.
Apelin levels in all three patient groups significantly
differed from apelin levels in healthy volunteers (254
[225–311] pmol/L). Specifically, patients with complete
nephrogenic DI had higher apelin levels (413 [332–504]
pmol/L; P  .01); and patients with complete central DI
(209 [174–241] pmol/L; P .02) and PP (190 [172–215]
pmol/L; P  .0001) had lower apelin levels compared to
healthy volunteers (Figure 1A).
Median copeptin levels were: in healthy volunteers, 4.1
(2.6–6.9) pmol/L; in patients with complete central DI,
1.9 [1.9–2.5] pmol/L; in patients with PP, 3.9 [2.2–4.7]
pmol/L; andwere highest in patientswith nephrogenicDI,
56.7 (39.7–70) pmol/L (Table 2).
The plasma apelin to copeptin ratio in patients with PP
(53 [38–92] pmol/pmol)was similar to healthy volunteers
(57 [37–102] pmol/pmol). In contrast, the plasma apelin
to copeptin ratio in patients with complete central DI (89
[73–135] pmol/pmol; P  .02) and in patients with com-
plete nephrogenic DI (7 [6–10] pmol/pmol;P .001) was
significantly lower compared to healthy volunteers (Fig-
ure 1B and Table 2).
Discussion
The main finding of our study is that apelin levels in pa-
tients with PPS differ significantly from healthy volun-
teers. Specifically, apelin levels are highest in patients with
complete nephrogenic DI and lower in patients with PP or
complete central DI as compared to healthy volunteers.
The colocalization of AVP and apelin in hypothalamic
magnocellularneuronsandthepresenceof their receptorson
theseneuronssuggestaninteractionbetweenAVPandapelin
(7). Accordingly, previous studies showed an interaction of
AVPandapelinboth inrodentsandhumans. Instatesknown
to be associated with elevated AVP release (eg, dehydration
or lactating rats), the central injection of the endogenous
peptide K17F inhibited the phasic electrical activity of AVP
neurons, leading to reduced AVP release in the blood circu-
lation and increased aqueous diuresis in rodents (5, 10). In
addition to this diuretic effect at a central level, there is also
aneffectof apelinat thekidney levelbecauseapelin receptors
arepresent in the collectingductsof thekidney.K17Factson
these receptors and herein inhibits AVP-induced cAMPpro-
ductionoccurringviaV2-Rs.This leads toanincreasedaque-
ousdiuresisbydecreasingaquaporin-2 insertion in theapical
membrane (6). Thus, the diuretic effect of apelin is not only
due to a central effect by inhibiting AVP release in the blood
circulation but also due to a direct renal action of apelin on
collecting ducts, by counteracting the antidiuretic effect of
AVP occurring via V2-R.
Inhealthy volunteers, increasingplasmaosmolality due
to hypertonic saline infusion was accompanied by a par-
allel, linear increase in plasma AVP concentration and by
a decrease in plasma apelin concentration. In contrast,
water loading led to a decrease in plasma osmolality and
AVP concentrations and to an increase in apelin concen-
trations (11). Thus, apelin together with AVP is involved
in the regulationof body fluid homeostasis in both rodents
and humans (11).
In contrast, in patients with an abnormal body fluid
homeostasis due to the syndrome of inappropriate anti-
Table 2. Plasma Apelin and Copeptin Levels in Healthy Volunteers and Patients With the PPS
Healthy





n 113 15 19 7
Plasma copeptin, pmol/L 4.1 (2.6–6.9)a 1.9 (1.9–2.5) 3.9 (2.2–4.7) 56.7 (39.7–70) .001c
Plasma apelin, pmol/L 254 (225–311) 209 (174–241) 190 (172–215) 413 (332–504) .001d
Plasma apelin/copeptin, pmol/pmol 57 (37–102)b 89 (73–135) 53 (38–92) 7 (6–10) .001e
Abbreviations: cDI, central DI; nDI, nephrogenic DI; hV, healthy volunteers. Data are expressed as median (interquartile range). P values are
according to the Kruskal-Wallis test.
a In one patient, the copeptin value is lacking.
b According to the lacking copeptin value, the apelin to copeptin ratio is also missing in one person.
c P values assessed with Dunn’s multiple comparison test for plasma copeptin: cDI vs hV, P  .001; PP vs hV, p  ns; nDI vs hV, P  .001; cDI vs
PP, p  ns; cDI vs nDI, P  .001; PP vs nDI, P  .001.
d P values assessed with Dunn’s multiple comparison test for plasma apelin: cDI vs hV, P  .02; PP vs hV, P  .001; nDI vs hV, P  .01; cDI vs PP,
P  ns; cDI vs nDI, P  .001; PP vs nDI, P  .001.
e P values assessed with Dunn’s multiple comparison test for plasma apelin to copeptin ratio: cDI vs hV, P  .02; PP vs hV, P  ns; nDI vs hV, P 
.001; cDI vs PP, P  ns; cDI vs nDI, P  .001; PP vs nDI, P  .003.
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diuretic hormone, plasma apelin levels show a parallel
increase togetherwithAVP.Specifically, apelin levelswere
shown tobe increased compared tohealthy controls; how-
ever, the increase of apelin levels was not able to compen-
sate for the elevated AVP levels, arguing for an inappro-
priate response of apelin in these patients contributing to
a disturbed body fluid homeostasis (12).
Similarly, and again in contrast to healthy volunteers,
also in patients with central or nephrogenic DI, apelin and
AVP/copeptin decrease or increase in parallel to each
other.We assume that these parallel changes in apelin and
AVP/copeptin level occurred to compensate for the failure
of AVP in order to re-establish a balance between the an-
tidiuretic effect of AVP and the diuretic effect of apelin.
However, apelin fails to fully compensate, resulting in a
disturbed body fluid homeostasis.
In patients with PPS, different pathologies result in in-
creased diuresis. Patients with central DI suffer fromAVP
deficiencymirrored by low plasma copeptin levels. In par-
allel, we found lower plasma apelin levels in patients with
central DI compared to healthy volunteers. However, the
plasma apelin to copeptin ratio of 89 (73–135) pmol/pmol
in patients with central DI is higher compared to healthy
volunteers (57 [37–102] pmol/pmol). Possibly, the de-
crease in plasma apelin levels of patients with central DI is
insufficient as compared to the decrease of AVP/copeptin
to re-establish a balance between the antidiuretic effect of
AVP and the diuretic effect of apelin, resulting in polyuria.
In patients with nephrogenic DI, we observed higher
apelin levels as compared to the healthy volunteers. Pa-
tients with nephrogenic DI are known to have a renal
resistance to AVP and have elevated plasma AVP and co-
peptin levels (16). Again, we hypothesize that this parallel
increase of apelin and copeptin is an effort of the apelin/
vasopressin-system to re-establish the water balance me-
diated by the two hormones. However, there is a renal
resistance to AVP together with an increase in apelin lev-
els,which results inpolyuria.According topublisheddata,
apelin seems to increase as estimated glomerular filtration
rate increases (17), suggesting that ahigher renal clearance
is associatedwith higher apelin levels. Based on these data
wewould expect rather lower apelin levels in patientswith
impairedkidney function;we therefore donot assume that
elevated apelin levels in patients with nephrogenic DI are
caused by the slightly impaired kidney function.
The pathophysiological mechanism of PP is not based
onadeficiencyor resistanceofAVPbut rather results from
an excessive fluid intake over an extended period of time
(16). Patients with PP had slightly but significantly lower
plasma apelin levels compared to healthy volunteers.
However, plasma copeptin levels and the plasma apelin to
copeptin ratio were similar in comparison to healthy vol-
unteers. The “normal” apelin to copeptin ratio in PP at-
tests forbalancedwaterhomeostasis,whereasplasmaape-
lin to copeptin ratio in central or nephrogenic DI is
increased or decreased compared to healthy volunteers,
reflecting a disturbed water homeostasis. Another inter-
esting explanation is that apelin itself might also be in-
volved directly in the pathogenesis of PP. Apelin immu-
noreactive cell bodies and fibers were found in rats in the
hypothalamus, more precisely in the anteroventral third
ventricle region (in the subfornical organ, the vascular
organ of the lamina terminalis, and the median preoptic
nucleus) (18). These structures are involved in the control
of drinking behavior (19, 20). Intracerebroventricular in-
jection of apelin-13 resulted in a significantly decreased
A
B
Figure 1. A, Plasma apelin concentrations (pmol/L) in healthy
volunteers (n  113) and in patients with central DI (n  15), PP (n 
19), and nephrogenic DI (n  7). Multiple comparisons were assessed
with Dunn’s multiple comparison test. B, Plasma apelin to copeptin
ratios (pmol/pmol) in healthy volunteers (n  112) and in patients with
central DI (n  15), PP (n  19), and nephrogenic DI (n  7). Multiple
comparisons were assessed with Dunn’s multiple comparison test. cDI,
central DI; nDI, nephrogenic DI.
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fluid intake in adultwater-deprived ratswith free access to
water (10). Low apelin levels in patients with PP could
therefore be the reason for the altered drinking behavior
leading to an inadequate fluid intake in these patients.
However, at present this is rather speculative, and further
studies are needed to investigate the underlying
mechanisms.
The following limitations of this study have to be
taken into account. First, this is a proof of concept
study, where we investigated plasma apelin levels in
patients with complete central or complete nephrogenic
DI and PP, whereas patients with partial central or par-
tial nephrogenic DI were not analyzed. Second, it is
rather a small sample size, and further studies with
larger patient numbers are needed to confirm our re-
sults. Third, the small sample size did not allow con-
ducting subgroup analysis in terms of age or sex, both
known to influence apelin levels. Nevertheless, taking
into consideration, that we provide for the first time
data about plasma apelin levels and the apelin to co-
peptin ratio in patients with PPS, we see our results as
interesting and noteworthy in terms of understanding
pathophysiological mechanisms of apelin, and AVP in
dysregulated body fluid homeostasis such as in patients
with PPS.
Conclusion
In conclusion, this study describes for the first time
plasma apelin levels in patients with PPS. We show that
apelin levels are highest in patients with nephrogenic DI
and lower in patients with PP or complete central DI com-
pared to healthy subjects. In contrast to healthy volun-
teers, where an inverse action of AVP/copeptin and apelin
is known, this study shows that in patients with central
and nephrogenicDI, AVP/copeptin and apelin decrease or
increase, respectively, in parallel with each other.
Thus, in patients with PP, the apelin to copeptin ratio
is similar compared to healthy volunteers, suggesting a
normalwater homeostasis,whereas, in patientswith com-
plete central or nephrogenicDI, the increasedor decreased
apelin to copeptin ratio, respectively, reflects a disturbed
osmotic and body fluid homeostasis. However, the phys-
iological relevance and interpretation of this ratio needs
further studies in a larger population of patients.
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